Botulism cases from Botox injections linked to Milton spa, health officials say
Ten people are suspected to have iatrogenic botulism, a rare but serious illness, after receiving a procedure at Rodrigo Beauty on Granite Avenue. Health officials advise that anyone who received Botox injections between May 1 and June 4 should contact their nearby health department or DPH.
Iatrogenic botulism can happen when Botox spreads beyond where it was injected. Symptoms of iatrogenic botulism include blurred or double vision, slurred speech, breathing difficulties, drooping eyelids, and difficulty swallowing. Some more serious cases may experience progressive muscle weakness. If you experience any of these symptoms, the DPH recommends visiting the nearest emergency room.
"Early recognition and treatment can significantly improve outcomes," the DPH said in a statement.
The DPH asks that anyone contact them with questions or concerns at 617-983-6800.
What is Botox?
Cosmetic botulinum toxin, commonly referred to as Botox injections, is a "purified substance derived from bacteria," according to the American Society of Plastic Surgeons. It blocks the nerve signal to the muscle, which prevents the muscle from moving. It is commonly used to prevent wrinkles in the face.
The Massachusetts DPH emphasizes that trained professionals should inject Botox and that the technique, use of non-FDA-approved products, and improper dosing increase the risk of botulism.
Massachusetts spa owner arrested
A Stoughton spa owner, with locations in Easton and Randolph, was arrested in November of 2024 for allegedly using illegal counterfeit Botox and filler injections. Thirty-eight-year-old Rebecca Fadanello allegedly performed thousands of injections using imported Botox, Sculptra, and Juvederm from China and Brazil. She purchased the products from Alibaba, a Chinese company that claims to sell products in bulk.
She was charged with one count of illegally importing merchandise contrary to law, one count of selling or dispensing a counterfeit drug, and one count of selling or dispensing a counterfeit device.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
John Gleeson, attorney and resilient polio survivor, dies at 86
The polio that afflicted him as a boy never left John Gleeson, but it never held him back. "He's someone who just never let anything bring him down," Gerry Gleeson II said Saturday, July 26, adding that the disease essentially paralyzed his father for two years of his childhood. Polio caused some life-long mobility challenges — though no one could blame the disease for Gleeson's penchant for wearing black Gold Toe socks with shorts — but it also contributed to a resiliency that made an impression on his family. "There was no obstacle — nothing was going to hold him back from whatever he was going to achieve," his son said. Gleeson, who earned a law degree at night while working as a teacher, became a beloved raconteur known for welcoming a constellation of engaging conversationalists into his West Bloomfield home long before he died July 18 at the age of 86. While Gleeson loved being a lawyer — "he liked the intellectual challenge, he liked being in court, he liked being before a jury," his son said — he also loved holding court at home. Gleeson and his wife Mary Ellen, who died in 2018, hosted dinner gatherings in which the conversation flowed along with fine wine. "In addition to all his other fine qualities, he was a wine connoisseur," said Steve Fishman, a prominent defense attorney who got to know him through Gerry Gleeson who, like his father, became an attorney. Gleeson, Fishman said, had "an unbelievable wine cellar." The Gleesons' passion for the grape led them to spend many winters in Napa Valley, the region in northern California known for hundreds of vineyards. Gleeson, known to his granddaughters as "Papa," also savored spending time with family. Gerry Gleeson said that even though his father was a "fiercely competitive" attorney (he specialized in environmental law and represented businesses), "he'd make a point to be home early to be with family." Even though Gleeson favored the conservative Fox News network, his experience with polio made him an early proponent of the COVID-19 vaccine, his son said, adding that his dad was "first in line" when it became available. Reflecting on his father's life and the time they spent together, Gerry Gleeson said one of the things he'll miss most is "sitting around the grill shooting the breeze." Gleeson's survivors include son John and granddaughters Madeleine, Sydney and Margaux. Visitation will be Monday, July 28 from 9 a.m. to 10 a.m. at Holy Name Catholic Church, 630 Harmon, Birmingham, followed by a funeral mass at 10 a.m. M.L. Elrick is a Pulitzer Prize- and Emmy Award-winning investigative reporter, director of student investigative reporting program Eye On Michigan, and host of the ML's Soul of Detroit podcast. Contact him at mlelrick@ or follow him on X at @elrick, Facebook at ML Elrick and Instagram at ml_elrick. This article originally appeared on Detroit Free Press: John Gleeson, attorney and resilient polio survivor, dies at 86 Solve the daily Crossword
Yahoo
28 minutes ago
- Yahoo
FDA approves SetPoint's neuroimmune modulation device for RA treatment
The US Food and Drug Administration (FDA) has approved SetPoint Medical's implantable neuroimmune modulation device, SetPoint System, to treat moderate-to-severe rheumatoid arthritis (RA) in adults. The system is designed for individuals who are inadequately managed by or intolerant to current RA therapies such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). The system is said to activate the body's natural anti-inflammatory and immune-restorative pathways by delivering electrical stimulation to the vagus nerve once a day. The neurostimulation therapy can potentially provide an alternative treatment without immune-compromising risks. The FDA approval was based on the outcomes of the RESET-RA study, a 242-patient double-blind, randomised, sham-controlled trial, which showed the system's efficacy and safety in this patient group. Patients tolerated the device placement procedure and the stimulation therapy well, with a low incidence of related serious adverse events at 1.7%. SetPoint Medical CEO Murthy Simhambhatla said: 'The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases. 'We are committed to improving the health of people living with RA, and look forward to working with providers and payers to make our innovative therapy accessible to their patients. We plan to introduce the SetPoint System in targeted US cities this year, followed by expansion across the country starting in early 2026.' SetPoint Medical is also exploring the use of its neuroimmune modulation platform for other autoimmune diseases such as multiple sclerosis (MS) and Crohn's disease. In March 2024, the company's neuroimmune modulation device secured a breakthrough device designation to treat relapsing-remitting MS. "FDA approves SetPoint's neuroimmune modulation device for RA treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
34 minutes ago
- Yahoo
IDEXX Laboratories Raises Full-Year Outlook Following Second-Quarter Beat
IDEXX Laboratories (IDXX) lifted its full-year outlook on Monday as the animal diagnostics and healt
